Editing Finasteride (section)

===Prostate cancer===
In males aged 55 years old and over finasteride decreases the risk of low-grade [[prostate cancer]] but may increase the risk of high-grade prostate cancer and has no effect on overall survival.<ref>{{Cite web |date=28 August 2013 |title=Finasteride for Prostate Cancer Prevention |url=https://www.cancer.gov/types/prostate/research/finasteride-reduces-low-grade |url-status=live |archive-url=https://web.archive.org/web/20200206153247/https://www.cancer.gov/types/prostate/research/finasteride-reduces-low-grade |archive-date=6 February 2020 |access-date=8 February 2020 |website=National Cancer Institute}}</ref>

A 2010 review found a 25% reduction in the risk of prostate cancer with 5α-reductase inhibitor.<ref name="pmid20977593">{{Cite journal |vauthors=Wilt TJ, Macdonald R, Hagerty K, Schellhammer P, Tacklind J, Somerfield MR, Kramer BS |year=2010 |title=5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review |journal=BJU Int. |volume=106 |issue=10 |pages=1444–51 |doi=10.1111/j.1464-410X.2010.09714.x |pmid=20977593 |s2cid=22178061 |doi-access=free}}</ref> A follow-up study of the [[Medicare (United States)|Medicare]] claims of participants in a 10-year Prostate Cancer Prevention Trial suggests the reduction in prostate cancer is maintained even after discontinuation of treatment.<ref>{{Cite journal |vauthors=Unger JM, Hershman DL, Till C, Tangen CM, Barlow WE, Ramsey SD, Goodman PJ, Thompson IM |date=March 2018 |title=Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial |journal=Journal of the National Cancer Institute |volume=110 |issue=11 |pages=1208–1215 |doi=10.1093/jnci/djy035 |pmc=6235685 |pmid=29534197}}</ref> However, 5α-reductase inhibitors have been found to increase the risk of developing certain rare but aggressive forms of prostate cancer (27% risk increase), although not all studies have observed this.<ref name="Hirshburg2016">{{Cite journal |vauthors=Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS |year=2016 |title=Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review |journal=J Clin Aesthet Dermatol |volume=9 |issue=7 |pages=56–62 |pmc=5023004 |pmid=27672412}}</ref> No impact of 5-α-reductase inhibitor on survival has been found in people with prostate cancer.<ref name="Hirshburg2016" />